Amoneta Diagnostics gains CE-marking for APO-Easy® Genotyping Kit under EU IVDR
Amoneta announces the CE-marking under the EU-IVDR of its APO-Easy® Genotyping Kit....
Nos Actualités
Amoneta Diagnostics at AD/PD™ 2025: APO-Easy® Genotyping kit in the Context of New Therapies’ Launch
Amoneta Diagnostics is pleased to announce its’ team’s participation to the AD/PD™ 2025 conference, a major international event that brings together experts in the field of Alzheimer’s and Parkinson’s disease. This year, the focus will be on APO-Easy®, our CE-IVDR certified genotyping kit that is designed to assess genetic risk for Alzheimer’s disease through the analysis of the APOE gene. With the launch of groundbreaking new treatments for Alzheimer’s disease, the need for ident...
Amoneta at CTAD 2024: Introducing our Research on Advancing Alzheimer’s Disease Stratification
We are excited to announce that our team will not only be attending but also presenting at the 2024 Clinical Trials on Alzheimer’s Disease (CTAD) conference. During the second poster session on October 31st, we will present our poster number 00492, which introduces an innovative approach to Alzheimer’s patient stratification by combining “static” genetic data from our APO-Easy® and NeuroDeGene® genotyping tools, with dynamic biomarker signatures through AI algorithms. Our resea...
Amoneta Diagnostics attends the AD/PD™ 2024 International Conference
Amoneta Diagnostics announces its participation in the forthcoming AD/PD™ 2024 International Conference on Alzheimer's and Parkinson's Diseases in Lisbon....
